Arrowhead Pharma in License Agreement With GSK for ARO-HSD
22 Noviembre 2021 - 03:55PM
Noticias Dow Jones
By Stephen Nakrosis
Arrowhead Pharmaceuticals Inc. on Monday said it entered an
exclusive license agreement with GlaxoSmithKline which will see GSK
develop and commercialize Arrowhead's ARO-HSD.
Arrowhead said ARO-HSD is an "investigational RNA interference
therapeutic in a Phase 1/2 trial that is currently being developed
as a treatment for patients with nonalcoholic steatohepatitis."
Arrowhead will receive an upfront payment of $120 million.
Arrowhead is also eligible for additional payments tied to future
trials and regulatory approval, as well as for commercial milestone
payments and royalties, according to the companies.
GlaxoSmithKline will receive an exclusive license to develop and
commercialize ARO-HSD in all territories except Greater China,
which will be retained by Arrowhead, the companies said.
The deal is expected to close in the first quarter of next
year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 22, 2021 16:40 ET (21:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024